Targets › PDGFRB
33 programs from 28 companies in 194 trials: 119 Phase 2, 47 Phase 1, 24 Phase 3, 4 Phase 4; Oncology, Respiratory, Other; next expected readout Dec 2026.
Tyrosine-protein kinase that acts as a cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth…. (UniProt, P09619)
Open in Phaseline: the race on PDGFRB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chia Tai Tianqing Pharmaceutical Group | Catequentinib Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor | KDR, FLT4, KIT, PDGFRB | Phase 4 | Medullary Thyroid Cancer; Advanced Hepatocellular Carcinoma (HCC); Metastatic Colorectal Cancer; Hepatocellular Carcinoma … | Dec 2026 |
| Gossamer Bio USA | Seralutinib Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Macrophage colony stimulating factor receptor inhibitor | KIT, PDGFRB, PDGFRA, CSF1R | Phase 3 | Pulmonary Arterial Hypertension | Dec 2026 |
| Daiichi Sankyo | Quizartinib Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor | CSF1R, FLT3, KIT, PDGFRB, PDGFRA | Phase 3 | Leukemia; Acute Myeloid Leukemia; Hepatic Impairment; Acute Myeloid Leukemia, Adult … | May 2027 |
| Jiangsu HengRui Medicine | Famitinib Stem cell growth factor receptor inhibitor; Vascular endothelial growth factor receptor 1 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | KIT, FLT1, FLT3, PDGFRB, PDGFRA | Phase 3 | Cervical Cancer; Triple-Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Breast Neoplasm … | May 2027 |
| Advenchen Laboratories | Catequentinib (AL3818) Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor | KDR, FLT4, KIT, PDGFRB | Phase 3 | Alveolar Soft Part Sarcoma | Dec 2027 |
| AB Science | Masitinib Fibroblast growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor | FGFR3, KIT, PDGFRB, PDGFRA | Phase 3 | Amyotrophic Lateral Sclerosis | Dec 2027 |
| Alliance for Clinical Trials in Oncology | Tivozanib Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 3 | Clear Cell Renal Cell Carcinoma | Nov 2037 |
| Roche | Sorafenib Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | RAF1, PDGFRB, KIT, FLT3, BRAF | Phase 3 | Unresectable Hepatocellular Carcinoma; AML (Acute Myeloid Leukemia); Locally Advanced Thyroid Gland Carcinoma; Hepatocellular Carcinoma … | – |
| M.D. Anderson Cancer Center | Sunitinib Malate Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Renal Cell Carcinoma; Malignant Neoplasms of Urinary Tract; Prostate Cancer | Dec 2026 |
| National Cancer Institute (NCI) | Sunitinib Malate Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Advanced Lymphoma; Metastatic Pancreatic Neuroendocrine Tumor | Dec 2026 |
| Avalyn Pharma | Nintedanib (AP02) Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF); Systemic Sclerosis; Telangiectasia, Hereditary Hemorrhagic; Non Small Cell Lung Cancer … | Dec 2026 |
| Sun Yat-sen University | Anlotinib Hydrochloride Multi-tyrosine kinase inhibitor targeting VEGFR, PDGFR, FLT1, KIT, and RET | VEGFR, PDGFRA, PDGFRB, FLT1, KIT | Phase 2 | Glioblastoma | Dec 2026 |
| Canadian Cancer Trials Group | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Advanced Rare Tumours | Dec 2026 |
| University of Miami | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Gastrointestinal Stromal Tumors | Dec 2026 |
| National Cancer Institute (NCI) | Imatinib Mesylate Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | ABL1, PDGFRB, KIT, BCR | Phase 2 | Chronic Myeloid Leukemia, BCR-ABL1 Positive; B Acute Lymphoblastic Leukemia; Inherited Bone Marrow Failure Syndrome | Mar 2027 |
| National Cancer Institute (NCI) | Sorafenib Tosylate Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | RAF1, PDGFRB, KIT, FLT3, BRAF | Phase 2 | Gastrointestinal Stromal Tumor; Acute Myeloid Leukemia; Advanced Malignant Solid Neoplasm | Mar 2027 |
| Sarcoma Alliance for Research through Collaboration | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Gastrointestinal Stromal Tumors | Jun 2027 |
| Mannkind | Nintedanib (MNKD-201) Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 2 | Idiopathic Pulmonary Fibrosis | Dec 2027 |
| American Society of Clinical Oncology | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Lymphoma, Non-Hodgkin | Dec 2027 |
| Bai-Rong Xia | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Ovary Cancer | Dec 2027 |
| Memorial Sloan Kettering Cancer Center | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 2 | Osteosarcoma | Mar 2028 |
| M.D. Anderson Cancer Center | Tivozanib Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 2 | Renal Cell Carcinoma | Nov 2028 |
| Novartis | Midostaurin Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor | FLT3, KIT, PDGFRB, PDGFRA, PRKD3 | Phase 2 | FLT3-mutated Acute Myeloid Leukemia; AML/MDS; Acute Myeloid Leukemia | May 2029 |
| Taiho Pharmaceutical | Imatinib Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor | ABL1, PDGFRB, KIT, BCR | Phase 1 | Gastrointestinal Stromal Tumors; Hematological Neoplasms; Tyrosine Kinase Inhibitors; Leukemia, Acute Lymphoblastic … | Dec 2026 |
| University of Florida | Tivozanib Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 1 | Bile Duct Cancer | Dec 2026 |
| AstraZeneca | cediranib Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor | KIT, PDGFRB, PDGFRA, FLT1, FLT4 | Phase 1 | Solid Tumors; Fallopian Tube Clear Cell Adenocarcinoma; Cervical Cancer; Mismatch Repair Proficient Colorectal Cancer … | Dec 2026 |
| Betta Pharmaceuticals | X-82 Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 1 | DDI (Drug-Drug Interaction); Hepatic Impairment (HI); Advanced Non-small Cell Lung Cancer (NSCLC); Vorolanib … | Jan 2027 |
| Etnova Therapeutics | ETN101 Multiple tyrosine kinase inhibitor targeting FLT3, KIT, VEGFR2, and PDGFRB | FLT3, KIT, VEGFR2, PDGFRB | Phase 1 | Hepatocellular Carcinoma | Mar 2027 |
| State University of New York at Buffalo | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 1 | Carcinoma, Renal Cell | Jul 2027 |
| University of Colorado, Denver | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 1 | Osteosarcoma | Aug 2027 |
| Rabin Medical Center | Sunitinib Macrophage colony stimulating factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor | CSF1R, KIT, FLT3, PDGFRB, PDGFRA | Phase 1 | Solid Tumors Refractory to Standard Therapy | Jan 2028 |
| National Cancer Institute (NCI) | Tivozanib (AV-951) Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 1 | Cholangiocarcinoma | Dec 2028 |
| Sun Yat-sen University | KDR2-2 suspension eyedrop VEGFR2 inhibitor with moderate PDGFRβ inhibition | KDR, PDGFRB | Phase 1 | Neovascular Glaucoma | – |
Acute Myeloid Leukemia (10) Hepatocellular Carcinoma (6) Gastrointestinal Stromal Tumors (5) Cervical Cancer (4) Breast Cancer (4) Soft Tissue Sarcoma (3) Non-Small Cell Lung Cancer (3) Non-small Cell Lung Cancer (3) Non Small Cell Lung Cancer (2) Alveolar Soft Part Sarcoma (2) Locally Advanced Thyroid Gland Carcinoma (2) Unresectable Hepatocellular Carcinoma (2)
small molecule (24), mixed (6), antibody (2), other (1)
National Cancer Institute (NCI) (4) Sun Yat-sen University (2) M.D. Anderson Cancer Center (2) Canadian Cancer Trials Group (1) Chia Tai Tianqing Pharmaceutical Group (1) Novartis (1) Avalyn Pharma (1) Alliance for Clinical Trials in Oncology (1) Gossamer Bio USA (1) University of Florida (1) Daiichi Sankyo (1) Mannkind (1) Etnova Therapeutics (1) Memorial Sloan Kettering Cancer Center (1) Advenchen Laboratories (1) Taiho Pharmaceutical (1) University of Colorado, Denver (1) AstraZeneca (1) Sarcoma Alliance for Research through Collaboration (1) Jiangsu HengRui Medicine (1)
KIT (29) PDGFRA (21) FLT3 (17) CSF1R (13) KDR (10) FLT4 (10) FLT1 (10) RAF1 (2) BRAF (2) ABL1 (2) BCR (2) PRKD3 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.